Cuorips Inc. (TYO:4894)

Revenue by Segment

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024
Period Ending	Mar 31, 2025	Mar 31, 2024
Regenerative Medicine Products	175.00M	23.00M
Regenerative Medicine Products Growth	660.87%	-
Total	175.00M	23.00M
Total Growth	660.87%	-

Revenue by Geography

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024
Period Ending	Mar 31, 2025	Mar 31, 2024
Japan	175.00M	23.00M
Japan Growth	660.87%	-
Total	175.00M	23.00M
Total Growth	660.87%	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 21, 2026

Data Sources Report a data error